Skip to content
At Apexian, our mission is straightforward:
Find safe and effective therapies that will improve the lives of patients with a number of life-threatening ailments
Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in a number of cancers1 as well as playing a role in a variety of inflammation and angiogenesis driven illnesses such as diabetic macular edema (DME), inflammatory bowel disease (ulcerative colitis, Crohn’s disease) and chemotherapy-induced peripheral neuropathy (CIPN). Our experienced team of research scientists and clinical specialists have completed a phase 1 study in patients with advanced cancers. Apexian is now preparing for further development of its lead compound.
1Cancers include; AML, colon, pancreatic, bladder and malignant peripheral nerve sheath tumors (MPNST)
Our science is unique and represents first-in-class therapeutic potential.
Inhibition of the APE1/Ref-1 redox protein affects signaling pathways critical to cancer cell survival. APX3330 has shown dramatic anti-cancer and anti-inflammatory effects in numerous pre-clinical models of human cancers. Our human studies will evaluate the efficacy and safety of APX3330 in patients with a variety of cancers and inflammation-related conditions that express the APE1/Ref-1 protein.
+ read more about the R&D at Apexian
Our focus is on developing drugs targeting the APE/1/REF-1 protein in multiple indications: one drug, one target, multiple indications.
Our clinical plan is focused on developing APX3330 for treatment of diseases controlled by the APE1/Ref-1 protein. These diseases constitute areas of high unmet medical need including cancers of the colon, pancreas, skin, blood, diabetic macular edema, inflammatory bowel disorders and prevention of chemotherapy induced peripheral neuropathy.
LATEST APEXIAN NEWS
April 8, 2021 //
OCUPHIRE INITIATES ZETA-1 PHASE 2 CLINICAL TRIAL INVESTIGATING APX3330 IN DIABETIC RETINOPATHY
FARMINGTON HILLS, Mich., GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR).